Metsera Inc(MTSR) - 2024 Q4 - Annual Results

Exhibit 99.1 Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o ...